Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway.
Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway.
Int J Infect Dis. 2023 Jan;126:10-13. doi: 10.1016/j.ijid.2022.11.009. Epub 2022 Nov 12.
We aimed to describe post-acute sequelae of SARS-CoV-2 infection (PASC) related symptoms 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection.
Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases.
No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants.
SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants.
我们旨在描述未接种疫苗和接种疫苗的突破性感染 SARS-CoV-2 参与者在 SARS-CoV-2 检测阳性后 3-15 个月出现的与 SARS-CoV-2 感染后长期后遗症(PASC)相关的症状。
挪威 COVID-19 队列的参与者在 2020 年 11 月至 2021 年 1 月期间完成了一份关于 PASC 相关症状的问卷,他们没有 SARS-CoV-2 检测阳性。大约一年后,同一批参与者完成了第二份问卷(其中还包括 Everyday Memory Questionnaire [EMQ]-13),大多数人仍然没有 SARS-CoV-2 检测阳性,但也包括未接种疫苗和接种疫苗的参与者,他们在问卷前 3-15 个月 SARS-CoV-2 检测阳性。在完成问卷时,通过逆转录定量聚合酶链反应确定了强制性挪威传染病监测系统中的实验室确诊的 SARS-CoV-2 状态(阳性或阴性拭子检测)。
在 SARS-CoV-2 检测阳性后 3-15 个月,未接种疫苗和接种疫苗的参与者在自我报告的 PASC 症状、呼吸困难、疲劳、嗅觉/味觉改变、注意力问题或 EMQ-13 评分方面没有差异。接种疫苗的参与者报告的记忆问题较少。
SARS-CoV-2 疫苗对 PASC 症状提供了轻微的保护,尽管接种疫苗的参与者报告的记忆问题比未接种疫苗的参与者少。